Algert Global LLC Travere Therapeutics, Inc. Transaction History

Algert Global LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$5.44 - $9.5 $24,316 - $42,465	4,470 Added 5.63%	83,840 $754,000
Q3 2023 Nov 13, 2023	BUY	$7.64 - $17.25 $206,814 - $466,957	27,070 Added 51.76%	79,370 $710,000
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $800,190 - $1.18 Million	52,300 New	52,300 $803,000
Q4 2022 Feb 13, 2023	SELL	$18.47 - $26.14 $188,394 - $266,628	-10,200 Reduced 17.7%	47,422 $997,000
Q3 2022 Nov 15, 2022	BUY	$22.91 - $28.63 $108,135 - $135,133	4,720 Added 8.92%	57,622 $1.42 Million
Q2 2022 Aug 15, 2022	BUY	$20.94 - $30.01 $581,713 - $833,677	27,780 Added 110.58%	52,902 $1.28 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $593,130 - $768,733	25,122 New	25,122 $647,000

199

85.2M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.35B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.